Two drugs are better than one at targeting tumours with B-RAF mutations
Friday, October 24, 2008 - 08:35
in Health & Medicine
In a proportion of human solid tumours, in particular melanomas (a form of skin cancer that is often resistant to chemotherapy), inappropriate activation of the MEK/ERK signalling pathway as a result of mutations in the B-RAF gene promotes tumour cell growth and survival...
Read the whole article on Science Centric
More from Science Centric
Related
- NIH study reveals new genetic culprit in deadly skin cancerMon, 31 Aug 2009, 13:31:56 EDT
- Gene required for radiation-induced protective pigmentation also promotes survival of melanoma cellsThu, 20 Nov 2008, 13:29:36 EST
- Researchers identify mechanism used by gene to promote metastasis in human cancer cellsMon, 29 Sep 2008, 17:49:25 EDT
- Combining targeted therapy drugs may treat previously resistant tumorsSun, 30 Nov 2008, 14:07:42 EST
- Monash researchers uncover cancer survival secretsMon, 11 Aug 2008, 13:07:28 EDT